Meyka AI API is live for developers.Start building.
Advertisement
Grifols, S.A.

Grifols, S.A. (GIKLY) Stock Competitors & Peer Comparison

See (GIKLY) competitors and their performances in Stock Market.

GIKLYPNK
HealthcareDrug Manufacturers - General
$5.39
$0.30(5.27%)
U.S. Market opens in NaNh NaNm
Advertisement

Peer Comparison Table: Drug Manufacturers - General Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
GIKLY$5.39-5.27%15B16.26$0.35+1.63%
BMYMP$400.00-57.46%814.6B1777.78$0.23+4.37%
RHHBY$51.45-0.24%329.5B19.98$2.56+3.03%
RHHVF$411.25-2.70%327.4B20.21$20.35+3.02%
RHHBF$408.08-0.64%324.8B20.04$20.36+3.04%
AZNCF$189.90-1.35%294.4B31.49$6.03+1.41%
NVSEF$144.88+0.70%276.4B20.76$6.98+3.27%
SNYNF$87.71+1.26%105.4B19.03$4.61+5.52%
GLAXF$24.66+3.01%98.9B12.91$1.91+3.64%
CHGCF$47.72+2.82%78.5B28.75$1.66+3.78%
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

GIKLY vs BMYMP Comparison June 2026

GIKLY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GIKLY stands at 15B. In comparison, BMYMP has a market cap of 814.6B. Regarding current trading prices, GIKLY is priced at $5.39, while BMYMP trades at $400.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GIKLY currently has a P/E ratio of 16.26, whereas BMYMP's P/E ratio is 1777.78. In terms of profitability, GIKLY's ROE is +0.08%, compared to BMYMP's ROE of +0.39%. Regarding short-term risk, GIKLY is less volatile compared to BMYMP. This indicates potentially lower risk in terms of short-term price fluctuations for GIKLY.Check BMYMP's competition here

Stock price comparison of stocks in the Healthcare Sector

Loading...

Frequently Asked Questions